RITSUKO KOMAKI to ErbB Receptors
This is a "connection" page, showing publications RITSUKO KOMAKI has written about ErbB Receptors.
Connection Strength
0.827
-
Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):317-24.
Score: 0.271
-
EGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: a secondary analysis of RTOG 0324. Radiother Oncol. 2014 Jul; 112(1):30-6.
Score: 0.255
-
Reply to v.R. Bhatt et Al and m.C. Chamberlain. J Clin Oncol. 2013 Sep 01; 31(25):3165-6.
Score: 0.060
-
Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol. 2013 Mar 01; 31(7):895-902.
Score: 0.058
-
HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Clin Cancer Res. 2009 Aug 01; 15(15):4829-37.
Score: 0.045
-
Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2007 Dec 01; 69(5):1534-43.
Score: 0.040
-
Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther. 2007 Feb; 6(2):471-83.
Score: 0.038
-
Epidermal growth factor receptor as a target to improve treatment of lung cancer. Clin Lung Cancer. 2004 May; 5(6):340-52.
Score: 0.031
-
Epidermal growth factor receptor, cyclooxygenase-2, and BAX expression in the primary non-small cell lung cancer and brain metastases. Clin Cancer Res. 2003 Mar; 9(3):1070-6.
Score: 0.029